Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence

Aspirin has long been recognized as a beneficial treatment for atherosclerotic cardiovascular disease (ASCVD) due to its antiplatelet effects. However, there is a need to more precisely identify individuals who would benefit from aspirin therapy for primary prevention in order to reduce the risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sukkari, Mohamad Hekmat, Al-Bast, Basma, Al Tamimi, Raad, Giesing, William, Siddique, Momin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509658/
https://www.ncbi.nlm.nih.gov/pubmed/37736358
http://dx.doi.org/10.1016/j.ajpc.2023.100579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509658/
https://www.ncbi.nlm.nih.gov/pubmed/37736358
http://dx.doi.org/10.1016/j.ajpc.2023.100579

Ejemplares similares